Results 101 to 110 of about 536,398 (346)

Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients

International Journal of Nephrology, 2014
Introduction. In this study, we aimed to demonstrate the correlation of FGF-23 levels with bone-mineral metabolism, anemia, and the treatment in dialysis patients. Methods.
Nilgül Akalin, Yıldız Okuturlar, Özlem Harmankaya, Asuman Gedıkbaşi, Selçuk Sezıklı, Sibel Koçak Yücel   +5 more
doaj   +1 more source

Regulation of fibroblast growth factor 23 (FGF23) in health and disease

FEBS Letters, 2019
Fibroblast growth factor 23 (FGF23) is mainly produced in the bone and, upon secretion, forms a complex with a FGF receptor and coreceptor αKlotho. FGF23 can exert several endocrine functions, such as inhibiting renal phosphate reabsorption and 1,25 ...
Ludmilla Bär, C. Stournaras, F. Lang, M. Föller   +3 more
semanticscholar   +1 more source

Fibroblast growth factor 23—Klotho and hypertension: experimental and clinical mechanisms

Pediatric nephrology (Berlin, West), 2020
Hypertension (HTN) and chronic kidney disease (CKD) are increasingly recognized in pediatric patients and represent risk factors for cardiovascular morbidity and mortality later in life.
M. Freundlich, G. Gamba, B. Rodriguez-Iturbe   +2 more
semanticscholar   +1 more source

Fibrous Dysplasia and Fibroblast Growth Factor-23 Regulation [PDF]

Current Osteoporosis Reports, 2013
Fibrous dysplasia (FD) is a skeletal disorder caused by activating mutations in Gsα that result in elevations in cAMP. A feature of FD is elevated blood levels of the bone cell-derived phosphaturic hormone, fibroblast growth factor-23 (FGF23). FGF23 regulates serum phosphorus and active vitamin D levels by action on proximal renal tubule cells.
Alison M, Boyce, Nisan, Bhattacharyya, Michael T, Collins   +2 more
openaire   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption

Bone Reports, 2021
Context: Fibroblast growth factor (FGF) 23 is a hormone that regulates serum phosphate levels, the excess action of which causes chronic hypophosphatemic rickets/osteomalacia.
Naoko Hidaka, Hajime Kato, Minae Koga, Masaki Katsura, Yuko Oyama, Yuka Kinoshita, Seiji Fukumoto, Noriko Makita, Masaomi Nangaku, Nobuaki Ito   +9 more
doaj   +1 more source

Fibroblast Growth Factor 23 and Inflammation in CKD [PDF]

Clinical Journal of the American Society of Nephrology, 2012
Summary Background and objectives Levels of fibroblast growth factor 23 (FGF23) and inflammatory markers are commonly elevated in CKD, and each is associated with adverse clinical outcomes. This study tested the hypothesis that FGF23 is independently associated with inflammation in CKD.
Jair, Munoz Mendoza, Tamara, Isakova, Ana C, Ricardo, Huiliang, Xie, Sankar D, Navaneethan, Amanda H, Anderson, Lydia A, Bazzano, Dawei, Xie, Matthias, Kretzler, Lisa, Nessel, L Lee, Hamm, Lavinia, Negrea, Mary B, Leonard, Dominic, Raj, Myles, Wolf   +14 more
openaire   +2 more sources

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Fibroblast Growth Factor 23: Mineral Metabolism and Beyond [PDF]

, 2017
Patients affected by chronic kidney disease (CKD) exhibit a high risk of cardiovascular mortality that is poorly explained by traditional risk factors. There is a growing awareness about the role of derangement of mineral metabolism that is currently accepted as a trigger and sustainer of cardiovascular disease (CVD) in CKD patients.
Grabner, Alexander, Mazzaferro, Sandro, CIANCIOLO, GIUSEPPE, Krick, Stefanie, CAPELLI, IRENE, ROTONDI, SILVERIO, RONCO, CLAUDIO, LA MANNA, GAETANO, Faul, Christian   +8 more
openaire   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source